Literature DB >> 19326571

Tanshinone IIA reduces lethality and acute lung injury in LPS-treated mice by inhibition of PLA2 activity.

Min Xu1, Ming-Qing Dong, Fa-Le Cao, Man-Ling Liu, Yan-Xia Wang, Hai-Ying Dong, Yu-Fang Huang, Yi Liu, Xiao-Bin Wang, Bo Zhang, Peng-Tao Zhao, Ying Luo, Wen Niu, Yan Cui, Zhi-Chao Li.   

Abstract

Tanshinone IIA (TIIA) is one of the main active components from Chinese herb danshen. Previous reports showed that TIIA reduced the production of pro-inflammatory mediators stimulated with lipopolysaccharide (LPS). However, the effects of TIIA on LPS-induced acute lung injury are not fully understood. Here, we observed the effects of TIIA on mortality and lung injury in LPS-treated mice and on LPS-induced pulmonary epithelial cell injury, and further studied the underlying mechanism. As revealed by survival study, pretreatment with TIIA reduced mortality of mice and prolonged their survival time. Meanwhile, TIIA pretreatment significantly improved LPS-induced lung histopathologic changes, decreased lung wet-to-dry and lung-to-body weight ratios, inhibited lung myeloperoxidase activity and reduced protein leakage. TIIA also alleviated LPS-induced pulmonary epithelial cell injury, as proved by methyl thiazolyl tetrazolium (MTT) and lactic dehydrogenase assay. Furthermore, TIIA suppressed LPS-induced phospholipase A2 (PLA2) activity in both lung homogenate and bronchoalveolar lavage fluid. TIIA also inhibited the metabolites of PLA2, which was confirmed by results of thromboxane B2, prostaglandin E2 and leukotriene B4 detection. Besides, TIIA in vitro inhibited LPS-induced PLA2 activity in a dose-dependent manner. Western blotting showed that TIIA markedly inhibited the activation of nuclear factor kappa B (NF-kappaB) in LPS-treated mice. Taken together, these data firstly provided the novel information that the protective role of TIIA against LPS-induced lung injury may attribute partly to the inhibition of PLA2 activity and NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326571     DOI: 10.1016/j.ejphar.2009.02.003

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Tetrahydrocoptisine protects rats from LPS-induced acute lung injury.

Authors:  Weifeng Li; Huimin Huang; Xiaofeng Niu; Ting Fan; Hua Hu; Yongmei Li; Huan Yao; Huani Li; Qingli Mu
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

2.  Tanshinone IIA therapeutically reduces LPS-induced acute lung injury by inhibiting inflammation and apoptosis in mice.

Authors:  Min Xu; Fa-le Cao; Yu-fei Zhang; Liang Shan; Xiao-ling Jiang; Xiao-jing An; Wei Xu; Xiu-zhi Liu; Xiao-yan Wang
Journal:  Acta Pharmacol Sin       Date:  2014-12-29       Impact factor: 6.150

Review 3.  Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.

Authors:  Yu-Qiong He; Can-Can Zhou; Lu-Yao Yu; Liang Wang; Jiu-Ling Deng; Yu-Long Tao; Feng Zhang; Wan-Sheng Chen
Journal:  Pharmacol Res       Date:  2020-09-29       Impact factor: 7.658

Review 4.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

5.  Tanshinone IIA alleviates lipopolysaccharide-induced acute lung injury by downregulating TRPM7 and pro-inflammatory factors.

Authors:  Jie Li; Yan Zheng; Ming-Xian Li; Chu-Wei Yang; Yu-Fei Liu
Journal:  J Cell Mol Med       Date:  2017-10-18       Impact factor: 5.310

6.  A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism.

Authors:  Anne L Robertson; Geoffrey R Holmes; Aleksandra N Bojarczuk; Joseph Burgon; Catherine A Loynes; Myriam Chimen; Amy K Sawtell; Bashar Hamza; Joseph Willson; Sarah R Walmsley; Sean R Anderson; Mark C Coles; Stuart N Farrow; Roberto Solari; Simon Jones; Lynne R Prince; Daniel Irimia; G Ed Rainger; Visakan Kadirkamanathan; Moira K B Whyte; Stephen A Renshaw
Journal:  Sci Transl Med       Date:  2014-02-26       Impact factor: 17.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.